Polymerase chain reaction

Anbio Biotechnology Made a Successful First Presence at AACC Middle East 2023

Retrieved on: 
Monday, October 16, 2023
IVD, Polymerase chain reaction, LAMP, FIA, Platinum, POCT, CLIA, Ambulance, LFA, Chemiluminescent immunoassay, Lateral flow test, Biotechnology, Medical device

FRANKFURT, Germany, Oct. 16, 2023 /PRNewswire/ --  Anbio Biotechnology ("Anbio"), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.

Key Points: 
  • FRANKFURT, Germany, Oct. 16, 2023 /PRNewswire/ --  Anbio Biotechnology ("Anbio"), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.
  • Anbio is the platinum sponsor of AACC Middle East this year.
  • This successfully presence has further showcased Anbio's commitment to advanced, affordable, reliable product solutions and made huge progress toward greater recognition in Middle East area.
  • "Anbio's official launch in the Middle East market at AACC Middle East 2023 is a milestone moment for the company, " said Michael Lau.

Global and Regional Rare Disease Genetic Testing Market Analysis & Forecasts Report 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Health, Genetics, Diagnosis, Incidence, Parent, Hospital, DSM-IV codes, Physician, Exome, Plasma, Research, SRL Diagnostics, Genome, Prevalence, PCR, BGI Group, NGS, DNA, CVS, Risk, SNV calling from NGS data, Sanger, Massive parallel sequencing, Metabolism, Amniocentesis, Genetic code, Disease, State Key Laboratories, R, Inherit, Genomics, Patient, Polymerase chain reaction, WES, WGS, Genetic counseling, Growth, Genetic testing, Region, National Centre for Foreign Animal Disease, Gene, Rare, Chromosome, Fetus, Cardiogenic shock, Serum, Birth, Gastroenterology, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

An Optimized AAV Sample Preparation Method for Robust Quantification of Viral Titers by PCR, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 11, 2023
Workflow, DNA, Polymerase chain reaction, AAV, Vivisection, Research, Nested polymerase chain reaction, DNASE1L1, EDTA, Genome, Laboratory, PCR, Vaccine

TORONTO, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into an optimal DNase-I application for digital polymerase chain reaction (dPCR) treatment for Adeno-associated virus (AAV) workflows. For AAV applications ranging from research tools to clinical-stage gene therapeutic strategies, the ability to quantify AAV vector concentration precisely and reproducibly is crucial. While several analytical methods are available, dPCR is one of the most robust and reliable ways to determine the absolute quantification of viral DNA at various stages of production.

Key Points: 
  • The featured speaker will discuss an optimized approach for PCR sample preparation that can be utilized at any stage of the AAV workflow (from harvest to polishing).
  • TORONTO, Oct. 11, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into an optimal DNase-I application for digital polymerase chain reaction (dPCR) treatment for Adeno-associated virus (AAV) workflows.
  • For AAV applications ranging from research tools to clinical-stage gene therapeutic strategies, the ability to quantify AAV vector concentration precisely and reproducibly is crucial.
  • Join Zoe Bowman, Research Associate, Teknova , for the live webinar on Wednesday, October 25, 2023, at 10am PDT (1pm EDT).

Molecular Designs releases their new Direct-PCR Covid/Flu/RSV Simplicity Panel™ product

Retrieved on: 
Tuesday, October 10, 2023
Workflow, Infection, GMP, Polymerase chain reaction, ISO, Simplicity, COVID-19, Molecular design software, Research, Laboratory, PCR, Management, Vaccine

BIRMINGHAM, Ala., Oct. 10, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Direct-PCR Covid/Flu/RSV Simplicity Panel™.

Key Points: 
  • BIRMINGHAM, Ala., Oct. 10, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Direct-PCR Covid/Flu/RSV Simplicity Panel™.
  • The Molecular Designs Direct-PCR Buffer is the fastest and easiest way of getting high-quality samples prepared for molecular testing.
  • Molecular Designs assays are manufactured to GMP and ISO 13485:2016 standards and are compatible with most PCR platforms.
  • "This innovative product enhancement further enables our laboratory clients to accelerate their workflow, lower expenses, and eliminate the time-consuming process of sample preparation," said Ted Kramm Chief Executive Officer at Molecular Designs.

Global and Regional Rare Disease Genetic Testing Market Report 2023-2033: Early Detection Demand and Innovative Systems Usher in New Era for Rare Disease Genetic Testing

Retrieved on: 
Tuesday, October 3, 2023
Chromosome, DNA, Sanger, National Centre for Foreign Animal Disease, Gastroenterology, Prevalence, BGI Group, DSM-IV codes, Serum, Disease, Fetus, Genomics, Parent, Hospital, Cardiogenic shock, SRL Diagnostics, NGS, Amniocentesis, CVS, Genetic testing, Research, Birth, Genetic code, Exome, Incidence, Genetic counseling, Plasma, Metabolism, Patient, Polymerase chain reaction, Physician, Risk, State Key Laboratories, WGS, Inherit, Growth, Diagnosis, Region, R, Rare, WES, SNV calling from NGS data, Massive parallel sequencing, Gene, PCR, Genome, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.

Key Points: 
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • Among the most prevalent rare disease genetic testing panels are those tailored for gastroenterology, endocrine and metabolic disorders, and neurological diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Broken String Biosciences Closes $15M Series A Funding Round

Retrieved on: 
Monday, September 18, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, DNA, Platform as a service, Broken String, Investment, Wellcome Genome Campus, NGS, Gene editing, Tencent, Genomics, Doctor of Philosophy, Cas9, Traction, Patient, Polymerase chain reaction, National Human Genome Research Institute, Biology, Growth, Safety, PCR, Genome, Data science, Antibiotics, Vaccine

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures).

Key Points: 
  • Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures).
  • As part of the round, Yoann Bonnamour, Mérieux Equity Partners, and Arnaud Autret, Illumina Ventures, join the Company’s Board of Directors.
  • Felix Dobbs, PhD, Chief Executive Officer of Broken String Biosciences, commented: “Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients.
  • This new funding will enable the technology to be developed and delivered in a format that meets the needs of all customers, ideally positioning the Company for significant growth.”
    To learn more about Broken String Biosciences, please visit brokenstringbio.com

8 Key Trends in the $106 Billion Worldwide IVD Market

Retrieved on: 
Thursday, August 31, 2023
EUA, Mayo Clinic, Immunochemistry, Test management, Coronavirus, NGS, COVID-19, 2005 in television, Danaher, Fujifilm, Ford, Research, Mass spectrometry, Biomarker, Exact sciences, Eli Lilly, Sherlock, Amazon, Siemens Healthineers, Acquisition, Polymerase chain reaction, Roche, Medicine, OTC, IVD, Growth, AI, POC, FDA, PCR, Medical device, Renewable energy, Pharmaceutical industry, Vaccine, Pfizer

ARLINGTON, Va., Aug. 31, 2023 /PRNewswire/ -- In vitro diagnostics (IVDs) remain dynamic. The IVD market is a high R&D spend industry with constant innovations and routine interest from venture capital firms in diagnostic products.  Nevertheless, the past few years have been very disruptive for IVDs. However, the resilient IVD industry has weathered the pandemic and is forging ahead with new technologies and increased opportunities that will sustain market growth through the foreseeable future.

Key Points: 
  • The IVD market is a high R&D spend industry with constant innovations and routine interest from venture capital firms in diagnostic products.
  • The global IVD test market is estimated at $106 billion in 2023 and is expected to grow 3.8% annually through 2028.
  • This conclusion is among the analysis found in The Worldwide Market for In Vitro Diagnostic Tests, 16th Edition , the brand new market research report from leading firm Kalorama Information.
  • Beyond these developments, Kalorama Information emphasizes several other key trends that will shape the present and future of IVD testing.

Astraveus Appoints Microfluidic expert Etienne Fradet as Chief Technical Officer

Retrieved on: 
Thursday, August 31, 2023
Microfluidics, CGT, Miniaturization, Polymerase chain reaction, PCR, École polytechnique, Doctor of Philosophy, Management

PARIS, Aug. 31, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Etienne Fradet as Chief Technical Officer.

Key Points: 
  • PARIS, Aug. 31, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Etienne Fradet as Chief Technical Officer.
  • Prior to joining Astraveus, he served in senior management positions at Stilla Technologies, a Paris-based microfluidic digital PCR (polymerase chain reaction) company.
  • Jérémie Laurent, Founder and Chief Executive Officer of Astraveus, said: "Etienne brings considerable experience and expertise that will be crucial to Astraveus as we enter the next stage of our development.
  • Etienne Fradet, Chief Technical Officer of Astraveus, added: "Astraveus is an innovative company with a unique approach and ambitious vision to transform patient access to these life-changing therapies.

Astraveus Appoints Microfluidic expert Etienne Fradet as Chief Technical Officer

Retrieved on: 
Thursday, August 31, 2023
Microfluidics, CGT, Miniaturization, Polymerase chain reaction, PCR, École polytechnique, Doctor of Philosophy, Management

PARIS, Aug. 31, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Etienne Fradet as Chief Technical Officer.

Key Points: 
  • PARIS, Aug. 31, 2023 /PRNewswire/ -- Astraveus SAS ("Astraveus" or the "Company"), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Etienne Fradet as Chief Technical Officer.
  • Prior to joining Astraveus, he served in senior management positions at Stilla Technologies, a Paris-based microfluidic digital PCR (polymerase chain reaction) company.
  • Jérémie Laurent, Founder and Chief Executive Officer of Astraveus, said: "Etienne brings considerable experience and expertise that will be crucial to Astraveus as we enter the next stage of our development.
  • Etienne Fradet, Chief Technical Officer of Astraveus, added: "Astraveus is an innovative company with a unique approach and ambitious vision to transform patient access to these life-changing therapies.

Avalon’s Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis

Retrieved on: 
Wednesday, August 30, 2023
Infection, Culture, TB, Brain, National Health Laboratory Service, LSM, Collection, Polymerase chain reaction, Lymph, Patient, MSO, PCR, Mycobacterium tuberculosis, Disease, Vaccine, Tuberculosis, MTB

FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient’s sputum sample. Avalon owns a 40% interest in LSM.

Key Points: 
  • FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient’s sputum sample.
  • LSM’s new polymerase chain reaction (“PCR”) test allows for accurate and rapid identification of Mycobacterium tuberculosis (“Mtb”) from samples.
  • The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.
  • This test also has a significantly higher throughput and much lower cost per test as compared to the standard diagnostic tests.